Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Levrat SM"" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł :
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.
Autorzy :
Seydoux C; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Medinger M; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland. .
Gerull S; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Halter J; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Heim D; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Chalandon Y; Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Levrat SM; Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Schanz U; Department of Medical Oncology and Hematology, Stem-/Immune- cell-transplant Unit, University Hospital of Zurich, Zurich, Switzerland.
Nair G; Department of Medical Oncology and Hematology, Stem-/Immune- cell-transplant Unit, University Hospital of Zurich, Zurich, Switzerland.
Ansari M; Department Women, Children and Adolescent, Unit of Oncology and Hematology Pediatric, University Hospital of Geneva, Geneva, Switzerland.; Cansearch Research Laboratory, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Simon P; Clinical Trials Unit, Department of Clinical Research, Basel University, Basel, Switzerland.
Passweg JR; Divisions of Hematology and Internal Medicine, Department of Medicine, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland. .
Cantoni N; Division of Oncology, Hematology and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jan; Vol. 100 (1), pp. 209-216. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Busulfan/*administration & dosage
Cyclophosphamide/*administration & dosage
Hematologic Neoplasms/*therapy
Hematopoietic Stem Cell Transplantation/*methods
Immunosuppressive Agents/*administration & dosage
Transplantation Conditioning/*methods
Adult ; Aged ; Busulfan/adverse effects ; Chemical and Drug Induced Liver Injury/diagnosis ; Chemical and Drug Induced Liver Injury/mortality ; Cyclophosphamide/adverse effects ; Drug Therapy, Combination ; Female ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/mortality ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Immunosuppressive Agents/adverse effects ; Male ; Middle Aged ; Prospective Studies ; Transplantation Conditioning/mortality ; Transplantation, Homologous/methods ; Transplantation, Homologous/mortality ; Young Adult
Czasopismo naukowe
Tytuł :
[Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Autorzy :
Yafour N; Établissement hospitalier et universitaire 1(er) Novembre 1954, service d'hématologie et de thérapie cellulaire, BP 4166, 31000 Ibn Rochd, Oran, Algérie; Université d'Oran 1, Ahmed Ben Bella, faculté de médecine, Oran, Algérie.
Beckerich F; Hôpital Henri-Mondor, service d'hématologie et de thérapie cellulaire, boulevard Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France.
Bulabois CE; Centre hospitalier universitaire, service d'hématologie clinique, 38043 Grenoble cedex 9, France.
Chevallier P; CHU de Nantes, service d'hématologie clinique, Hôtel-Dieu, place Alexis-Ricordeau, 44035 Nantes, France.
Daguindau É; CHRU de Besançon, service d'hématologie, 3, boulevard Fleming, 25000 Besancon, France.
Dumesnil C; CHU de Rouen, service d'hémato-oncologie pédiatrique, 1, rue de Germont, 76031 Rouen cedex, France.
Guillaume T; CHU de Nantes, service d'hématologie clinique, Hôtel-Dieu, place Alexis-Ricordeau, 44035 Nantes, France.
Huynh A; IUCT-Oncopole, service d'hématologie et de greffe de cellules souches hématopoïétiques, 1, rue Irène-Joliot-Curie, 31059 Toulouse cedex, France.
Levrat SM; Division of hematology, department of medical specialties, Geneva university hospitals, 4, rue Gabrielle-Perret-Gentil, 1205 Geneva, Suisse.
Menard AL; Centre Henri-Becquerel, service d'hématologie clinique, rue d'Amiens, CS 11516, 76038 Rouen cedex 1, France.
Michallet M; Centre hospitalier Lyon Sud, service d'hématologie clinique, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France.
Pautas C; Hôpital Henri-Mondor, service d'hématologie et de thérapie cellulaire, boulevard Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France.
Poiré X; Universitaires Saint-Luc, section of hematology cliniques, 1200 Brussels, Belgique.
Ravinet A; CHU Clermont-Ferrand, service de thérapie cellulaire et d'hématologie clinique adulte, 63100 Clermont-Ferrand, France; Université Clermont-Auvergne, EA7453 et CIC-501, 63003 Clermont-Ferrand, France.
Yakoub-Agha I; CHRU de Lille, université de Lille 2, département de maladie du sang, LIRIC Inserm U995, 59000 Lille, France. Electronic address: .
Bazarbachi A; American university of Beirut, medical center, P.O. Box 113-6044 Beirut, Liban.
Pokaż więcej
Transliterated Title :
Stratégies préventives et thérapeutiques de la rechute après allogreffe de cellules souches hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).
Źródło :
Bulletin du cancer [Bull Cancer] 2017 Dec; Vol. 104 (12S), pp. S84-S98. Date of Electronic Publication: 2017 Nov 26.
Typ publikacji :
Journal Article; Practice Guideline; Review
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Hematologic Neoplasms/*therapy
Secondary Prevention/*standards
Antineoplastic Agents/therapeutic use ; Bortezomib/therapeutic use ; Central Nervous System Neoplasms/prevention & control ; Central Nervous System Neoplasms/secondary ; Genetic Markers ; Hematologic Neoplasms/genetics ; Hematologic Neoplasms/prevention & control ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/prevention & control ; Lymphoma/drug therapy ; Maintenance Chemotherapy/standards ; Multiple Myeloma/drug therapy ; Neoplasm, Residual ; Prognosis ; Protein Kinase Inhibitors/therapeutic use ; Recurrence ; Retreatment/methods ; Retreatment/standards ; Secondary Prevention/methods
Czasopismo naukowe
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies